Barclays analyst Raimo Lenschow maintains Teradata (NYSE:TDC) with a Underweight and raises the price target from $33 to $35.
Nemaura Medical Receives First Purchase Order From U.S. Health Provider HealthFleet; The Purchase Order Consists Of 75,000 ProBEAT Glucose Sensors Over An Initial Five Month Period And Is Valued At $500,000 In Revenue
Nemaura to integrate its proBEATTM glucose sensors with HealthFleet's proven RestoreHealth wellness program targeted at U.S.
Nemaura Medical, Inc. (NASDAQ:NMRD)("Nemaura" or the
